The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mo ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.